Image

Global Osteoporosis Drug Market – Industry Trends and Forecast to 2030

Pharmaceutical

Image

Global Osteoporosis Drug Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Sep 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Osteoporosis Drug Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 15,576.30 USD Million
Diagram Market Size (Forecast Year) USD 20,332.57 USD Million
Diagram CAGR %

Major Markets Players

  • GlaxoSmithKline
  • F. Hoffmann La Roche
  • Novartis
  • Eli Lilly And Company
  • Astrazeneca

Global Osteoporosis Drug Market, By Type (Primary Osteoporosis and Secondary Osteoporosis), Therapy Type (Hormone Replacement Therapy and Bisphosphonate Therapy), Treatment Type (Medication and Surgery), Mechanism of Action Type (Bisphosphonates, Selective Estrogen Receptor Modulators and Bone Resorption Inhibitors), Route of Administration Type (Oral, Intravenous, Subcutaneous and Others),  End-Users (Hospitals, Homecare, Specialty Clinics and  Others) – Industry Trends and Forecast to 2030.

Osteoporosis Drug Market

Osteoporosis Drug Market Analysis and Size

The global osteoporosis drug market is experiencing steady growth driven by factors such as the increasing aging population, rising prevalence of osteoporosis, and growing awareness about bone health. Data Bridge Market Research analyses that the osteoporosis drug market which was USD 15,576.30 million in 2022, would rocket up to USD 20,332.57 million by 2030, and is expected to undergo a CAGR of 4.68% during the forecast period. This indicates that the market value. “Medication” dominates the treatment type segment of the osteoporosis drug market owing to the growing demand for medication treatment due to rise in prevalence of osteoporosis globally. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Osteoporosis Drug Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021(Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

By Type (Primary Osteoporosis and Secondary Osteoporosis), Therapy Type (Hormone Replacement Therapy and Bisphosphonate Therapy), Treatment Type (Medication and Surgery), Mechanism of Action Type (Bisphosphonates, Selective Estrogen Receptor Modulators and Bone Resorption Inhibitors), Route of Administration Type (Oral, Intravenous, Subcutaneous and Others),  End-Users (Hospitals, Homecare, Specialty Clinics and  Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

GlaxoSmithKline plc. (U.K.), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Eli Lilly And Company. (U.S.), Astrazeneca (U.K.), Pfizer Inc. (U.S.), Takeda Pharmaceutical Company Limited. (Japan), Bristol-Myers Squibb Company (U.S.), Sanofi (France), Johnson & Johnson Services, Inc.(U.S.), Bayer AG (Germany), AbbVie Inc. (U.S.), Allergan (Ireland), Merck & Co., Inc. (U.S.), Amgen Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Novo Nordisk A/S (Denmark), DAIICHI SANKYO COMPANY (Japan), LIMITED. and Cipla Inc. (India)

Market Opportunities

  • Introduction of innovative treatment therapies for osteoporosis
  • Increasing number of healthcare and pharmaceutical facilities globally
  • Rising research and development opportunities

Market Definition

Osteoporosis is a condition of bone weakening or bones becomes fragile and likely to break. In other words, osteoporosis is a condition wherein the bone density decreases. This is specially witnessed in old age people. Osteoporosis brings along back pain, stooped posture, bone fracture and tooth loss.

Osteoporosis Drug Market Dynamics

Drivers

  • Increasing Prevalence of Osteoporosis

The prevalence of osteoporosis is increasing worldwide mainly due to changing lifestyles, poor diet and sedentary lifestyle. Factors that contribute to osteoporosis, such as reduced physical activity, insufficient intake of calcium and vitamin D and hormonal imbalances. The increasing number of people suffering from osteoporosis is creating a significant demand for osteoporosis drugs

  • Increased Awareness and Diagnosis

Awareness of osteoporosis and its consequences has increased significantly among both health professionals and the general public. Initiatives by health organizations, patient advocacy groups, and pharmaceutical companies have played an important role in educating people about osteoporosis prevention, early detection, and available treatment options. As a result, more and more people are diagnosed with osteoporosis, increasing the demand for osteoporosis drugs

  • Technological Advances in Drug Development

Technological advances in drug development have made it possible to discover and develop more effective and targeted treatments for osteoporosis. The use of advanced imaging techniques, molecular biology and genomics has provided insight into the pathophysiology of osteoporosis and led to the identification of new drug targets. The development of new drug delivery systems and formulation techniques will also improve the efficacy and patient compliance of osteoporosis medications 

  • Growing Investment for Healthcare Facilities

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities

Opportunities

  • Targeted Therapies and Personalized Medicine

The development of targeted therapies and personalized treatment approaches offers the opportunity to improve the effectiveness and safety of osteoporosis treatment. Advances in genomics, biomarker identification and precision medicine enable specific patient subgroups that may benefit from tailored treatment. By developing innovative treatment methods that meet the individual characteristics and needs of the patient, treatment results can be improved and products can be differentiated in the market 

  • Research and Development for New Drug Candidates

Ongoing research and development in the field of osteoporosis offers opportunities for the discovery and development of new drug candidates. Exploring new mechanisms of action, identifying innovative drug targets and exploiting advances in drug delivery systems can lead to the development of innovative therapies with greater efficacy and fewer side effects. Companies that invest in RandD to expand their product portfolio can take advantage of these opportunities and gain a competitive advantage in the market 

Restraints

  • Patent Expiration and Generic Competition

Many osteoporosis drugs have had patent expirations, allowing generic versions to enter the market. Generic drug competition often leads to lower prices, which reduces the revenue potential of originator drug manufacturers. This may affect profitability and hinder the growth of the osteoporosis drug market 

  • Side Effects and Safety Concerns

Osteoporosis medications, such as all medications, can have potential side effects and safety concerns. Some medications have been associated with rare but serious side effects, such as atypical fractures and osteonecrosis of the jaw. These safety concerns may lead to regulatory actions, warnings, and restrictions affecting the prescribing and marketing of certain osteoporosis drugs

Challenges

  • High Development Costs and Long Development Times

Developing and marketing a new osteoporosis drug requires significant research and development costs, including preclinical studies, clinical trials and regulatory notifications. The process can be time-consuming and often takes years from initial discovery to commercialization. In addition, the high failure rate of clinical trials further increases costs and lengthens development schedules. These challenges increase the financial burden on pharmaceutical companies and create uncertainty about the return on invested capital 

  • Reimbursement and Pricing Pressures

Osteoporosis drugs, especially the newer biologics, can be expensive. Pricing pressures from health systems, payers and insurance companies can limit the availability and affordability of these drugs. Reimbursement policies, formulary restrictions, and cost containment measures can affect market access, patient affordability, and overall market demand. Pharmaceutical companies must overcome these challenges to secure favourable reimbursement and pricing agreements while demonstrating the value and cost-effectiveness of their products 

This osteoporosis drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Osteoporosis Drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Recent Developments

  • In August 2021, Enzene Biosciences Ltd received Marketing Authorization (MA) from the Drug Controller General of India (DCGI) for its biosimilar drug, denosumab, indicated for the treatment of osteoporosis in adults
  • In January 2021, Theramex, a London-headquartered pharmaceutical company, launched the osteoporosis medicine Livogiva in Europe

Global Osteoporosis Drug Market Scope

The osteoporosis drug market is segmented on the basis of type, therapy type, treatment type, mechanism of action, route of administration and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Primary osteoporosis
  • Postmenopausal osteoporosis
  • Senile osteoporosis
  • Idiopathic osteoporosis
  • Seocndary osteoporosis

Therapy type

Treatment type

Mechanism of Action

  • Bisphosphonates
  • Alendronate
  • Ibandronate
  • Risedronate
  • Zoledronic
  • Selective Estrogen Receptor Modulators
  • Raloxifene
  • Bone Resorption Inhibitors
  • Denosumab

Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Others

End-User

  • Hospitals
  • Homecare
  • Specialty clinics
  • Others

Osteoporosis Drug Market Regional Analysis/Insights

The osteoporosis drug market is analysed and market size insights and trends are provided by country, type, therapy type, treatment type, mechanism of action, route of administration and end-users as referenced above.

The countries covered in the osteoporosis drug market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the osteoporosis drug market owing to the easy availability of osteoporosis drugs and rising prevalence of osteoporosis.   

Asia-Pacific is projected to score highest growth rate for the forecast period owing to rising expenditure to develop healthcare infrastructure coupled with growth and expansion of life sciences industry.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The Osteoporosis drug market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Osteoporosis drug market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Osteoporosis Drug market. The data is available for historic period from 2021 to 2030.

Competitive Landscape and Osteoporosis Drug Market Share Analysis

The osteoporosis drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to osteoporosis drug market.

Some of the major players operating in the osteoporosis drug market are

  • GlaxoSmithKline plc. (U.K.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Novartis AG (Switzerland)
  • Eli Lilly And Company. (U.S.)
  • Astrazeneca (U.K.)
  • Pfizer Inc. (U.S.)
  • Takeda Pharmaceutical Company Limited. (Japan)
  • Bristol-Myers Squibb Company (U.S.)
  • Sanofi (France)
  • Johnson & Johnson Services, Inc.(U.S.)
  • Bayer AG (Germany)
  • AbbVie Inc. (U.S.)
  • Allergan (Ireland)
  • Merck & Co., Inc. (U.S.)
  • Amgen Inc. (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Novo Nordisk A/S (Denmark)
  • DAIICHI SANKYO COMPANY (Japan), LIMITED.
  • Cipla Inc. (India)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The osteoporosis drug market size will be worth USD 20,332.57 million by 2030.
The growth rate of the osteoporosis drug market is 4.68% by 2030.
Increasing Prevalence of Osteoporosis, Increased Awareness and Diagnosis & Technological Advances in Drug Development are the growth drivers of the osteoporosis drug market.
Type, therapy type, treatment type, mechanism of action, route of administration and end users are the factors on which the osteoporosis drug market research is based.
Major companies in the osteoporosis drug market are GlaxoSmithKline plc. (U.K.), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Eli Lilly And Company. (U.S.), Astrazeneca (U.K.), Pfizer Inc. (U.S.), Takeda Pharmaceutical Company Limited. (Japan), Bristol-Myers Squibb Company (U.S.), Sanofi (France), Johnson & Johnson Services, Inc.(U.S.), Bayer AG (Germany), AbbVie Inc. (U.S.), Allergan (Ireland), Merck & Co., Inc. (U.S.), Amgen Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Novo Nordisk A/S (Denmark), DAIICHI SANKYO COMPANY (Japan), LIMITED. and Cipla Inc. (India),
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials